

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

NOTIFICATION OF BOARD MEETING

The board of directors (the “**Board**”) of Innovative Pharmaceutical Biotech Limited (the “**Company**”) hereby announces that a meeting of the Board will be held on Monday, 29 November 2021 for the purposes of, among other matters, considering and approving the consolidated interim results of the Company and its subsidiaries for the six months ended 30 September 2021.

By Order of the Board
Innovative Pharmaceutical Biotech Limited
Tang Rong
Executive Director

Hong Kong, 12 November 2021

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive director), Mr. Gao Yuan Xing (executive director), Mr. Tang Rong (executive director), Ms. Xiao Yan (non-executive director), Ms. Wu Yanmin (non-executive director), Ms. Chen Weijun (independent non-executive director), Mr. Wang Rongliang (independent non-executive director) and Mr. Chen Jinzhong (independent non-executive director).